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Abstract 
The colonic region of GIT has become an increasingly important site for drug delivery and absorption. This 
site specific delivery of drug to lower parts of the GIT is advantage for localized treatment of several colonic 
disease like colon cancer, crohn’s disease, ulceratice colitis, IBD, diarrhea etc. colon targeted drug delivery 
system (CTDDS) ensure direct treatment at the disease site and avoiding the systemic side effects. It is 
suitable for absorption site for protein and peptide drugs. Cytochrome P450 3A class of drug metabolizing 
enzyme, have lower activity in colon.  This review, mainly compares the primary approaches for (CTDDS) 
Colon targeted Drug Delivery system namely prodrugs, pH and time dependent systems, and microbially 
triggered systems, which achieved limited success and had limitations as compared with newer CDDS 
namely pressure controlled colonic delivery capsules, CODESTM, and osmotic controlled drug delivery 
which are unique in terms of achieving in vivo site specificity, and feasibility of manufacturing process. 
Keywords: Colon segments, microbial triggered, Cytochrome P450 3A, CTDDS approaches. 
 
INTRODUCTION 
Colon Targeted Drug Delivery System (CTDDS) may 
be following the concept of Controlled or Sustained 
drug Delivery System. For CTDDS oral route of 
administration has received most attention. Local 
delivery allows topical treatment of inflammatory bowel 
disease. Colon is highly desirable for local treatment of 
a variety of bowel diseases such as ulcerative colitis, 
Crohn’s disease, colonic cancer, local treatment of 
colonic pathologies, and systemic delivery of protein 
and peptide drugs [1,2]. For effective  and safe therapy of 
these colonic disorders, colon specific drug delivery is 
necessary i.e. drug release and absorption should not 
occur in the stomach as well as the small intestine, and 
neither the bioactive agent should be degraded in either 
of the dissolution sites but only released and absorbed 
once the system reaches the colon [3]. Today, colon 
specific drug delivery is challenging task to 
pharmaceutical technologist. 
The colon is believed to be a suitable absorption site for 
peptides and protein drugs for the following reasons, (i) 
less diversity, and intensity of digestive enzymes, (ii) 
comparative proteolytic activity of colon mucosa is 
much less than that observed in the small intestine, thus 
CDDS protects peptide drugs from hydrolysis, and 
enzymatic degradation in duodenum and jejunum, and 
eventually releases the drug into ileum or colon which 
leads to greater systemic bioavailability [4].  The 
concentration of drug reaching the colon depends on 
formulation factors, the extent of retrograde spreading 
and the retention time [5]. Coating of the drugs with pH-
sensitive polymers provides simple approach for colon-
specific drug delivery [6]. The bioactive agent should be 
degraded in either of the dissolution sites but only 
released and absorbed once the reaches the colon. 
Because the colon has a long residence time 72 hours 
and high water content it favors absorption of poorly 
absorbed drug molecule may have an improved 
bioavailability, CDDS has been employ to achieve 
following objectives i) Sustained delivery to reduce 
dosing frequency ii) Delay delivery of drug to achieve 
high concentration in treatment of disease of distal gut 
iii) to delay deliver to a time appropriate to treat acute 
phase of disease iv) Deliver drug to that region that is 
less hostile metabolically, drug which is acid and 
enzyme labile such as proteins[7]. 
 
Benefits of Colon Target Drug Delivery System: 
a) Reducing the adverse effects in the treatment of 
colonic diseases (ulcerative colitis, colorectal 
cancer, Crohn’s disease etc.) 
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b) Minimizing extensive first pass metabolism of 
steroids. 
c) Preventing the gastric irritation produced by oral 
administration of NSAIDS. 
d) High retention time thus increasing the 
bioavailability of poorly absorbable drugs. 
e) Increased patient compliance.  
f) Colon is an ideal site for the delivery of agents to 
cure the local diseases of the colon.  
 
Fig 1: Anatomy of colon 
 
Limitation of Colon Target Drug Delivery System 
a) Difficult to access colon. 
b) Incomplete release of drug. 
c) Multiple manufacturing steps. 
d) Parental route is expensive and inconvenient. 
e) Lower surface area and relative tightness of the 
tight junctions in the colon can restrict drug [8] 
 
Need of Colon Targeted Drug Delivery System 
The Colonic region of the GIT has Became an 
increasingly important site for drug delivery and 
absorption. CDDS offers therapeutic benefits of patients 
in both local and systemic treatment. Systems utilize 
natural material that are degraded by colonic bacterial 
enzyme and have high commercial viability. It ensures 
direct treatment at the disease site, lower dosing and 
fewer systemic side effects. Colon-specific formulation 
could also be used to prolong the drug delivery. Such 
inflammatory conditions are usually treated with 
glucocorticoids and Sulphasalazine Formulations for 
colonic delivery are also suitable for delivery of drugs 
which polar and/or susceptible to chemical and 
enzymatic degradation in the upper GI tract highly 
affected by hepatic metabolism, in particular, 
therapeutic proteins and peptides. It also provide 
opportunity to clarify the mechanism of action of some 
non-steroids anti- inflammatory drugs (NSAID) such as 
sulfide which get metabolized in the colon to the active 
moiety and interfere with the proliferation of colon 
polyps (first stage in colon cancer) probably in local 
mode. Large intestine is potential site for absorption of 
protein drugs. 
 
Criteria for Selection of Drug for Colon Targeted 
Drug Delivery System: 
a. Colon Targeted Drug Delivery System which 
show poor absorption from the stomach or 
intestine including peptides and protein. 
b. The selection of Polymer for particular drugs 
depends on the physiochemical nature of the 
drug as well as the disease for which the 
system is to be used. Factors such as chemical 
nature, stability and partition 
c. Coefficient of the drug and type of absorption 
enhancer chosen influence the carrier selection.  
d. Drugs poorly absorbed from upper GIT. 
e. Drug for colon cancer drugs that degrade in 
stomach and small intestine. 
f. Drugs that undergo extensive first pass 
metabolism. 
 
Part of GIT Transit time  
 Fasted state 
 Fed state 
 Small intestine transit 
 Colon transit  
10min – 2hr 
  >2hr 
 3-4hr 
 20-35hr  
Table 1: Transit time of different parts of GIT Anatomy 
and Physiology of colon 
 
The GIT consists of parts from mouth to anus. It mainly 
consists of two parts namely stomach, intestine. 
Intestine is further divided into two small intestine and 
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large intestine [9]. The large intestine extending from 
the ileocecal junction to the anus is divided in to three 
main parts. These are the colon, the rectum and anal 
canal. The entire colon is about 5 feet (150 cm) long, 
and is divided in to five major segments. Peritoneal 
folds called as mesentery .peritoneal is supported by 
ascending and descending colon. The right colon 
consists of the cecum, ascending colon, hepatic flexure 
and the right half of the transverse colon. The left colon 
contain the left half of the transverse colon, descending 
colon, splenic flexure and sigmoid. The rectum is the 
last anatomic segment before the anus. 
A. Physiological factors 
I. Gastric emptying :- 
      Part of GIT             pH 
Stomach  Fasted state 1.5-2 
Fed state 2-6 
Small Intestine                6.6-7.5 
Colon 
Ascending colon 
Transverse colon 
Descending colon 
              
              6.4 
              6.6 
              7.0 
Table 2: pH in different parts of Colon 
Drug delivery to the colon upon oral administration 
depends mainly on gastric emptying and bowel transit 
time. Smaller particles have more transit time compared 
to larger particles. Diarrhoea patients have shorter 
transit time whereas constipation patients have longer 
transit time [10]. 
 
II.  pH of colon 
The food intake, diseased state, etc. influences the pH of 
the GIT. The changes in the pH along the 
gastrointestinal tract have been used as a means for 
targeted colon drug delivery. Radio telemetry shows the 
highest pH (7.5±0.7) in the terminal ileum. On entry 
into the colon, the pH drop to (6.4±0.6). The pH in the 
mid colon is (6.6±0.8) and in the left colon (7.7±0.7). 
There is a fall in pH on entry into the colon due to the 
presence of short chain fatty acids arising from bacterial 
fermentation of polysaccharides. For example lactose is 
fermented by the colonic bacteria to produce large 
amounts of lactic acid resulting in pH drop to about 5.0. 
Microorganism      Enzyme  Metabolic 
reaction 
 E.coli, 
Bacteroids  
       
Nitroreductase  
Reduces aromatic 
& heterocyclic 
nitro compounds  
Clostridia, 
Lactobacilli  
Hydrogenase  Reduces carbonyl 
groups & aliphatic 
double bonds  
Clostridia, 
Eubacteria  
Glucosidase  Cleavage of β-
glycosidase of 
Alcohols, phenols  
Eubacteria, 
Clostridia, 
Streptococci  
Sulfatase  Cleavageof 
Osulphates & 
Sulfamates 
Table 3: Different microflora, enzymes released and 
action 
 
III. Colonic microflora and enzymes 
A large number of anaerobic and aerobic bacteria are 
present in the entire length of the human GI tract. 
Intestinal enzymes are used to trigger drug release in 
various parts of the GIT. Usually, these enzyme are 
derived from gut micro flora residing in high numbers 
in the colon. These enzyme are used to degrade coatings 
or matrices as well as to break bonds between an inert 
carrier as an active agent (i.e. release of a drug from a 
prodrug). Over 400 distinct bacterial species have been 
found 20-30% of which are of the genus bacteroids. The 
concentration of bacteria in the human colon is around 
1000 CFU/ml .The most important anaerobic bacteria 
are Bacteroides, Bifidobacterium, Eubacterium,  
peptococcus, and peptostreptococcus, Ruminococcus , 
Ruminococcus , Clostridium. 
 
2.Pharmaceutical factors 
I. Drug candidates  
Due to high retention time of colon, colon causes an 
increase in the absorption of poorly absorbed agents like 
peptides, etc. drugs used for treatment of inflammatory 
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bowel diseases, etc. are suitable for colon targeted drug 
delivery system [11]. 
 
II. Drug carriers 
The selection of carrier for CDDS depends on the nature 
of the drug, disease for which the drug is used. The 
various physicochemical factors of drug that affect the 
carrier selection include chemical nature, stability, 
partition coefficient, functional groups of drug molecule 
etc. 
 
COLONIC DISEASES: 
 Acute colitis 
 Adenoma carcinoma of colon 
 Adenoma of colon 
 Collagenous colitis 
 Crohn’s disease  
 Diverticulitis 
 Ulcerative colitis 
 Inflammatory bowel disease (IBD)         
 Colonic Cancer 
 
APPROACHES FOR COLON TARGETED DRUG 
DELIVERY [12] 
 
1. Primary approaches for colon targeted drug 
delivery 
a. pH sensitive polymer coated drug delivery system 
b. Delayed release drug delivery system 
c. Microbially triggered drug delivery 
 i.  Prodrug approach 
 ii. Polysaccharide based system 
2. New approaches for colon targeted drug delivery 
a. Pressure controlled drug delivery system (PCDDDS) 
b. CODE 
c. Osmotic controlled drug delivery system (OROS-CT) 
d. Pulsatile 
i. Pulsincap system 
ii. Port system 
e. Azo hydrogels 
f. Multiparticulate system based drug delivery 
Fig 3: Design of Enteric coated-timed release press coated 
tablets (ETP tablets). 
a) pH sensitive polymer coated drug delivery 
system:- 
The pH varies in different parts of the gastrointestinal 
tract. The pH in stomach ranges between 1 and 2 during 
fasting. The pH in the proximal part of small intestine is 
6.5 and in distal part of small intestine it is 7.5. The pH 
is 6.4 in caecum, 5.7 in ascending colon, 6.6 in 
transverse colon and 7.0 in descending colon. The 
polymers described as pH-dependent in colon specific 
drug delivery are insoluble at low pH levels but become 
increasingly soluble as pH rises. Although a pH-
dependent polymer can protect a formulation in the 
stomach and proximal small intestine, it may start to 
dissolve even in the lower small intestine, and the site-
specificity of formulations can be poor.[13]. The decline 
in pH from the end of the small intestine to the colon 
can also result in problems Lengthy lag times at the 
ileo-cecal junction or rapid transit through the ascending 
colon can also result in poor site-specificity of enteric-
coated single-unit formulations [14]. 
Class  Examples 
Disaccharides  Lactose, Maltose  
Oligosaccharides  Cyclodextrins, Lactulose, 
Raffinose, Stachyose 
Polysaccharides  Alginates, Amylose,                      
Cellulose, Chitosan, 
Starch,Chondroitin sulphate, 
pectin, xanthan gum, etc. 
Table.5. Different polymers used for CDDS based on 
Microbial drug delivery system 
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b) Delayed (Time controlled release system) release 
drug delivery to colon  
Transit time dependent colonic DDS such as sustained 
or delayed release dosage forms are one of important 
drug release systems. However, due to potentially large 
variations of gastric emptying time of dosage forms in 
humans, in these approaches, colon arrival time of 
dosage forms cannot be accurately predicted, resulting 
in poor colonical availability. The dosage forms may 
also be applicable as colon targeting dosage forms by 
prolonging the lag time of about 5 to 6 h. However, the 
disadvantages of this system are:-1) Gastric emptying 
time varies markedly between subject or in a manner 
dependent on type and amount of food intake. 2) 
Gastrointestinal movement, especially peristalsis or 
contraction in the stomach would result in change in 
gastrointestinal transit of the drug. 3) Accelerated transit 
through different regions of the colon has been observed 
in patients with the IBD, the carcinoid syndrome and 
diarrhea and the ulcerative colitis. Therefore time 
dependent systems are not ideal to deliver drugs to 
colon specifically for the treatment of colon related 
diseases. On the other hand in  the stomach, the drug 
release should be suppressed by a pH sensing function 
(acid resistance) in the dosage form, which would 
reduce variation in gastric residence time. Therefore 
time dependent systems are not ideal to deliver drugs to 
colon specifically for the treatment of colon related 
diseases [15]. 
 
Fig.4 Pulsincap system 
 
c) Microbial triggered drug delivery system  
The microflora of the colon is in the range of 1011-1012 
Cfu/ml consisting mainly of anaerobic bacteria, e.g.  
Eubacteria, Clostridia, Enterococci, Enterobacteria and 
Ruminococcusetc. These microfloras fulfills its energy 
needs by fermenting various types of substrates that 
have been left undigested in the small intestine, like di- 
and trisaccharides, polysaccharides etc. For this 
fermentation, the micro floras produce a vast number of 
enzymes like glucoronidase, xylosidase, arabinosidase, 
galactosidase, nitroreductase, azareductase, deaminase, 
and urea dehydroxylase. Because of the presence of the 
biodegradable enzyme only in the colon, the use of 
biodegradable polymers for colon specific drug delivery 
seems to be a more site-specific approach as compared 
to other approaches.  
 
(i) Prodrug approach for drug delivery to colon  
Prodrug [16] is the main approach of microbial 
triggered drug delivery system in which the drug release 
from the formulation is triggered by the microflora 
present in the gut. Prodrug is the inactive form of an 
active parent drug that undergoes enzymatic 
transformation to release the active drug at the target 
site. This approach involves covalent linkage between 
the drug and its carrier in such a manner that upon oral 
administration the moiety remains intact in the stomach 
and small intestine. e.g. The produrgs are prepared by 
linking the active drug with hydrophobic moieties like 
amino acids, glucoronic acids, glucose, galactose, 
cellulose, etc. These Prodrug molecules get hydrolysed 
in the presence of the enzymes released by the 
microflora. The main drawback of this approach is that 
the formulation depends on the functional groups 
available on drug moiety for chemical linkage.  The 
prodrugs formed upon linkage results in the formation 
of new chemical entities that need a lot of evaluation 
before using them as carriers. The most widely used 
prodrug approach is the metabolism of azo compounds 
by intestinal bacteria like azoreducatase-galactosidase , 
β – xylosidase, nitroreductase, glycosidase deaminase, 
etc.  
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(ii)Polysaccharide based delivery systems  
Polysaccharide based delivery system is the other form 
of microbial triggered drug delivery system. Naturally 
occurring polysaccharides like guar gum, xanthan gum, 
chitosan, alginates, etc. are used in targeting the drug 
delivery. These are broken down by the colonic 
microflora to simple saccharides [17]. They can be easily 
modified chemically, biochemically, and are highly 
stable, safe, nontoxic, hydrophilic and gel forming and 
in addition, are biodegradable.  
 
[B]NEWLY DEVELOPED APPROACHES FOR 
CDDS 
a)Pressure-controlled drug-delivery systems  
Digestion mainly occurs due to the contractility of the 
stomach and peristaltic movement of the intestine. The 
contractility movement of stomach leads to the 
digestion or breakdown of larger particles to smaller 
ones which are then transferred to intestine. drug release 
occurs following the disintegration of a water-insoluble 
polymer capsule because of pressure in the lumen of the 
colon. The thickness of the ethylcellulose membrane is 
the most important factor for the disintegration of the 
formulation [18]. The system can be modified to 
withstand and rupture at different pressuresby changing 
the size of the capsule and thickness of the capsule shell 
wall.  
 
b) CODES technology: 
This method is developed to minimize the problems 
associated with the pH and time dependent drug 
delivery systems. In this system the pH sensitive 
polymers are used along with the polysaccharides that 
are degraded only by specific bacteria present in the 
intestine. CODESTM is a combined approach of pH 
dependent and microbially triggered CDDS. It has been 
developed by utilizing a unique mechanism involving 
lactulose, which acts as a trigger for site specific drug 
release in the colon . The system consists of a traditional 
tablet core containing lactulose, which is over coated 
with and acid soluble material, Eudragit E, and then 
subsequently over coated with an enteric material, 
Eudragit L. The acid soluble material coating then 
protects the preparation as it passes through the alkaline 
pH of the small intestine[19]. Once the tablet arrives in 
the colon, the bacteria enzymetically degrade the 
polysaccharide (lactulose) into organic acid. This lowers 
the pH surrounding the system sufficient to effect the 
dissolution of the acid soluble coating and subsequent 
drug release [20]. 
 
C) Osmotic Controlled Drug Delivery (ORDS-CT) 
The OROS-CT system can be a single osmotic unit or 
may incorporate as many as 5-6 push-pull units, each 4 
mm in diameter, encapsulated within a hard gelatin 
capsule. Each bilayer push pull unit contains an osmotic 
push layer and a drug layer, both surrounded by a 
semipermeable membrane. An orifice is drilled through 
the membrane next to the drug layer. Immediately after 
the OROS-CT is swallowed, the gelatin capsule 
containing the push-pull units dissolves. Because of its 
drug-impermeable enteric coating, each push-pull unit is 
prevented from absorbing water in the acidic aqueous 
environment of the stomach, and hence no drug is 
delivered. Swelling of the osmotic push compartment 
forces drug gel out of the orifice at a rate precisely 
controlled by the rate of water transport through the 
semipermeable membrane. For treating ulcerative 
colitis, each push pull unit is designed with a 3-4 h post 
gastric delay to prevent drug delivery in the small 
intestine. Drug release begins when the unit reaches the 
colon. OROS-CT units can maintain a constant release 
rate for up to 24 hours in the colon or can deliver drug 
over a period as short as four hours. Recently, new 
phase transited systems have come which promise to be 
a good tool for targeting drugs to the colon.52-55 
Various in vitro / in vivo evaluation techniques have 
been developed and proposed to test the performance 
and stability of CDDS[21]. 
 
d) Pulsatile colon targeted drug delivery  
a)Pulsincap system  
It is the capsule formulation. The plug placed in the 
capsule controls the release of the drug. 
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Swellable  hydrogels are used to seal the drug contents. 
The capsule [22] gets swelled when it comes in contact 
with the dissolution fluid and after a lag time the plug 
gets pushed off from the capsule and the drug will be 
released. Polymers such as different grades of hydroxyl 
propyl methyl cellulose (HPMC), poly methyl 
methacrylate and polyvinyl acetate are used as hydrogel 
plugs. The lag time is controlled by the length and point 
of intersection of the plug in the capsule body.  
b) Port system: 
The capsule body is enclosed in a semi permeable 
membrane. The capsule body consists of an insoluble 
plug consisting of osmotically active agent and drug 
formulation. When the capsule comes in contact with 
the dissolution fluid the semi permeable membrane 
permits the fluid flow into the capsule resulting in the 
development of pressure in the capsule body which 
leads to release of drug due to expelling of the plug. The 
drug is released at regular intervals with time gap 
between the successive intervals. 
c) Azo hydrogels: 
The pH sensitive monomers and azo cross linking 
agents in the hydrogel produce the colon specificity. 
During their passage through the GIT these hydrogels 
swell as the pH increases. This swelling of hydrogels 
cleaves the cross links in the hydrogel network causing 
the release of drug entrapped in the hydrogel. These 
hydrogels are prepared by cross linking polymerization 
of N- substituted (meth) acrylamides, N- tert- butyl 
acrylamide and acrylic acid with 4, 4-di 
(methacryloylamino) azobenzene as cross linking 
agents. The hydrogels are also prepared by crosslinking 
polymeric precursors, polymer- polymer reaction using 
same polymeric precursor with the corresponding 
copolymer containing side chains terminating in NH2 
groups.The degradation rate of hydrogel is associated 
with the degree of swelling and inversely proportional 
to the cross linking density.[22] 
d) Multi particulate system based drug delivery:- 
The various advantages of multiparticulate systems are 
increased bioavailability, reduced risk of local 
irritation,reduced risk of systemic toxicity. The various 
multiparticulate approaches include pellets, 
microparticles, granules and nanoparticles.These 
systems pass through the GIT easily due to their smaller 
size. Multiparticulate systems are dispersed more 
uniformly in the GIT resulting in more uniform drug 
absorption. 
 
Drug Delivery Index (DDI) and Clinical Evaluation 
of Colon- Specific Drug Delivery Systems 
DDI is a calculated pharmacokinetic parameter, 
following single or multiple dose of oral colonic 
prodrugs. DDI is the relative ratio of RCE (Relative 
colonic tissue exposure to the drug) to RSC (Relative 
amount of drug in blood i.e. that is relative systemic 
exposal to the drug). High drug DDI value indicates 
better colon drug delivery. Absorption of drugs from the 
colon is monitored by colonoscopy and intubation. 
Currently, gamma scintigraphy and high frequency 
capsules are the most preferred techniques employed to 
evaluate colon drug delivery systems 
 
Advantages of Colonic Drug Delivery 
a. Targeted drug delivery to the colon in treatment of 
colonic disease ensures direct treatment at the affected 
area with lower dose and less systemic side effects.    
b. The colonic drug delivery can also be utilized as the 
threshold entry of the drugs into blood for proteins and 
peptides which degraded or poorly absorbed in upper 
GIT.  
c. The colon targeted drug delivery can also be used for 
chronotherapy for effective treatment of diseases like 
asthma and angina. 
d. Minimizes first pass metabolism.  
e. Decreased frequency of administration. Hence 
decreased cost of drugs 
f. High retention time thus increasing the bioavailability 
of poorly absorbable drugs. 
 
Disadvantages of Colonic Drug Delivery  
a. There are variations among individuals with respect 
to the pH level in the small intestine and colon which 
may allow drug release at undesired CSDDS site.  
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b. The pH level in the small intestine and caecum are 
similar which reduces site specificity of formulation  
c. The major disadvantage of colonic delivery of drug is 
poor site specificity.    
d. Diet and diseases can affect colonic micro flora 
which can negatively affect drug targeting to colon . 
e. Nature of food present in GIT can affect drug 
pharmacokinetics.  
f. Enzymatic degradation may be excessively slow 
which can cause interruption in polymer      degradation 
and thus alters the release profile of drugs . 
 
CONCLUSION 
CDDS offers therapeutic benefits to the patient in both 
local and systemic treatment. System utilize natural 
material that are degraded by colonic bacterial enzyme 
and having high commercial viability. For in-vitro 
evaluation the current dissolution methods are not 
suitable. For that, Research is going to evaluate better 
dissolution techniques for CTDDS. Targeted drug 
delivery system is preferred for having instability, low 
solubility and short half life, large volume of 
distribution, poor absorption, low specificity and low 
therapeutic index. CTDDS  provide maximum 
therapeutic effects. 
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